All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Annals of Hematology

Volumn 95, Issue 12, 2016, Pages 1931-1942

  Schlenk, Richard F ^a,b   Lübbert, Michael ^c   Benner, Axel ^b   Lamparter, Alexander ^a   Krauter, Jürgen ^d,e   Herr, Wolfgang ^f,g   Martin, Hans ^h   Salih, Helmut R ⁱ   Kündgen, Andrea ^j   Horst, Heinz A ^k   Brossart, Peter ^l   Götze, Katharina ^m   Nachbaur, David ⁿ   Wattad, Mohammed ^o   Köhne, Claus Henning ^p   Fiedler, Walter ^q   Bentz, Martin ^r   Wulf, Gerald ^s   Held, Gerhard ^t   Hertenstein, Bernd ^u   Salwender, Hans ^v   Gaidzik, Verena I ^a   Schlegelberger, Brigitte ^e   Weber, Daniela ^a   Döhner, Konstanze ^a   Ganser, Arnold ^v   Döhner, Hartmut ^a   for the German Austrian Acute Myeloid Leukemia Study Group, ^w   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l UNIVERSITY HOSPITAL BONN   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p KLINIKUM OLDENBURG   (Germany)

^q UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^r STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^s UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^t SAARLAND UNIVERSITY   (Germany)

^u KLINIKUM BREMEN MITTE   (Germany)

^v ASKLEPIOS KLINIK ALTONA   (Germany)

^w NONE

more..

Author keywords

Acute myeloid leukemia; All trans retinoic acid; Nucleophosmin 1

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; NUCLEOPHOSMIN; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PROCEDURES; SURVIVAL RATE; TRENDS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84989824805     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2810-z     Document Type: Article

References (39)

1. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–21
2. Lo-Coco F, Di Donato L, Schlenk RF (2016) Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med 374(12):1197–8
3. Hu ZB, Minden MD, McCulloch EA (1995) Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia 9:1667–73
4. Yang GS, Minden MD, McCulloch EA (1993) Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 7:1012–9
5. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE et al (1999) Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13:1881–92
6. Ketley NJ, Allen PD, Kelsey SM, Newland AC (1997) Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte–macrophage colony-stimulating factor. Blood 90:4578–87
7. Hu ZB, Minden MD, McCulloch EA (1998) Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood 92:1768–75
8. Carter BZ, Milella M, Altieri DC, Andreeff (2001) Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97:2784–90
9. Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA et al (2016) Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med 213(4):483–97
10. Bradbury DA, Aldington S, Zhu YM, Russell NH (1996) Down-regulation of bcl-2 in AML blasts by alltrans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol 94:671–675
11. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U et al (2011) Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 118(11):3096–3106
12. Hajj HE, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O et al (2015) Retinoic acid and arsenic trioxide trigger degradation of mutated NPM-1 resulting in apoptosis of AML cells. Blood 125(22):3447–54
13. Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F et al (2015) Arsenic trioxide and all-trans-retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood 125(22):3455–65
14. Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A et al (1995) All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of poor prognosis acute myeloid leukemia. Leukemia 9:1121–5
15. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H et al (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478–84
16. Burnett AK, Milligan D, Hills RK, Goldstone AH, Prentice AG, Wheatley K et al (2004) Does all-trans retinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia? Results from 1666 patients in three MRC trials. Blood 104:1794
17. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and highrisk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–24
18. Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK (2006) Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AMLHR randomized trial. Blood 107:4614–22
19. Schlenk RF, Fröhling S, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F et al (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18:1798–803
20. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F et al (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia – results from AMLSG Trial AML HD98B. Haematologica 94:54–60
21. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y et al (2010) The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115:948–956
22. Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA et al (2014) Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. Blood 123(26):4027–36
23. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 3rd edn. IARC Press, Lyon
24. Mitelman F (ed): ISCN (1995): An international system for human cytogenetic nomenclature. Basel, Switzerland, Karger, 1995
25. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909–18
26. Schlenk RF, Dohner K, Mack S, Stoppel M, Király F, Götze K et al (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28(30):4642–4648
27. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649
28. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346
29. Andersen P, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann Stat 10:1100–1120
30. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474
31. Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York
32. R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
33. Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J et al (2012) Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol 30(29):3604–3610
34. Burnett AK, Hills RK, Friis LS, Kjeldsen L, Milligan D, Hunter AE et al (2013) The ATRA question in AML: lack of benefit overall or in any molecular subgroup in the NCRI AML16 trial. Blood 122(21):493
35. Lencer WI, von Andrian UH (2011) Eliciting mucosal immunity. N Engl J Med 365(12):1151–3
36. Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A et al (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 121(23):4769–77
37. Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J et al (2016) RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. doi:10.1038/leu.2016.126
38. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28(22):3636–43
39. Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L et al (2015) ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica 100(3):324–30